Please provide your email address to receive an email when new articles are posted on . Men were significantly younger and underwent surgery faster after diagnosis compared with women. No sex-related ...
Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have pinpointed a combination immunotherapy treatment that enhances the immune response for people with malignant gliomas, an ...
Enrollment of Older Patients in Cancer Treatment Trials in Canada: Why is Age a Barrier? Tumors of glial origin consist of a core mass and a penumbra of invasive, single cells, decreasing in numbers ...
Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have pinpointed a combination immunotherapy treatment that enhances the immune response for people with malignant gliomas, an ...
Researchers at the University of Alabama at Birmingham have identified a chemical pathway that may be associated with seizures and shorter patient survival in some patients with malignant glioma, the ...
Approximately 18,500 persons are diagnosed with malignant glioma in the United States annually. Few studies have investigated the comprehensive economic costs. We reviewed the literature to examine ...
This drug is for previously untreatable low grade IDH-mutant glioma, the most common malignant primary brain tumor in adults. This is the first major advance in decades for patients diagnosed with low ...
The MarketWatch News Department was not involved in the creation of this content. SINGAPORE, Dec. 18, 2025 (GLOBE NEWSWIRE) -- NeuExcell Therapeutics announced encouraging clinical results of NXL-004, ...
U.P. Oncolytics, a Helix 51 incubator company, has gained federal Orphan Drug designation, helping to fast-track development and reduce funding barriers for its Zika virus-based therapy to treat ...
Exousia Pro Inc.’s subsidiary, Exousia AI, has received orphan drug designation from the FDA for its exosome-based treatment for malignant glioma.
OSLO, Norway, July 1, 2025 /PRNewswire/ -- Hemispherian AS, a pioneering biotech company developing next-generation therapeutics for aggressive cancers, announced today that the U.S. Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results